Nicox Warrants Update
Nicox Issues Reminder: June 2024 Warrants Set to Expire by June 19, 2026
Nicox SA has issued a final reminder that its June 2024 warrants will expire on June 19, 2026 — less than two weeks away. Holders who do not act will lose all value on their warrants. Yahoo Finance reported the deadline applies to warrant ISIN FR001400QEQ3, issued as part of a June 2024 equity offering that raised €3.3 million for the French ophthalmology company.
The warrants are currently "in the money." The exercise price is €0.275 per new share, while Nicox's stock traded at roughly €0.374 on June 5, 2026 — a 36% premium over the strike price. That gap gives holders a financial reason to exercise rather than walk away empty-handed.
Key Dates Every Warrant Holder Must Know
Trading in the warrants on Euronext Growth Paris ends at market close on June 16, 2026. Three days later, on June 19, 2026, the exercise window closes for good at market close. Any warrants not exercised by that moment expire worthless. MarketScreener confirmed these as the two hard deadlines holders must plan around.
The conversion math is straightforward. Five warrants equal two new Nicox shares. With 10,022,595 warrants still outstanding as of March 31, 2026, full exercise would create roughly 4,009,038 new shares. That would bring Nicox approximately €1.1 million in fresh cash, according to Financial Content.
How These Warrants Came From a 2024 Survival Financing
Nicox issued these warrants in June 2024 during a difficult stretch. The company needed cash to keep its lead drug, NCX 470, moving through clinical trials. The equity offering closed on June 19, 2024, raising €3.3 million in gross proceeds. Ocumension Therapeutics, Nicox's largest shareholder at 4.82%, was a key participant in that deal, according to Yahoo Finance.
Since then, the picture has changed dramatically. In January 2026, Nicox fully repaid its debt to Kreos Capital, a unit of BlackRock, clearing all security over company assets. Revenue grew from €7.9 million in 2024 to €16.8 million in 2025. Net losses shrank from €22.4 million to just €2.4 million over the same period.
NCX 470 Drug Approval Push Makes Warrants More Valuable
The biggest reason these warrants are in the money is the success of NCX 470, Nicox's glaucoma eye drop. The Phase 3 "Denali" trial delivered positive results in August 2025. The drug lowers eye pressure by roughly 10 mmHg — a strong result for a glaucoma treatment. Kowa Company, Nicox's U.S. and Japan partner, is covering the cost of an FDA New Drug Application expected in summer 2026, said MarketScreener.
Nicox CEO Gavin Spencer said outstanding warrants "represent a potential source of additional funding for the Company, if exercised." Some analysts have set a 12-month price target of €1.00 per share — about 167% above current levels — based largely on that expected FDA filing. Spencer added that shareholder support at the June 24, 2026 General Meeting would be "key to support the Company's future activities."
Dilution Risk Is Real but Limited for Existing Shareholders
Not everyone is cheering. If all outstanding warrants are exercised, about 4 million new shares enter the market. That would dilute existing holders by roughly 0.25 percentage points on a fully diluted basis — shrinking a 1% stake to about 0.75%. Some retail investors on French finance forums have flagged this "dilution fatigue" as a concern, especially as the company approaches its high-value NDA submission window.
For most holders, the math still favors acting. With the share price above the €0.275 strike price, letting the warrants expire means leaving real money on the table. The clock runs out June 19, 2026. Nicox's cash runway already extends beyond 2027, so the €1.1 million from full exercise is a bonus — not a lifeline — for the company going forward, according to Financial Content.
Sentiment
NeutralPublishers
4
Articles
4
Reach
4
